Search results
3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With Less Than $100 Right Now | The...
The Motley Fool· 2 days agoIf you have an extra $100 to invest, you could set yourself up with dividends from Realty Income (O...
I Couldn’t Escape Poison Oak. So I Started Eating It.
The Wall Street Journal· 4 days agoBy that decade, a raft of poison-ivy-extract pills and shots could be purchased from companies...
Pfizer offers up to $250 million to settle thousands of Zantac cancer lawsuits, FT reports
WHTC 1450 Holland· 6 days ago(Reuters) - Pfizer has agreed offer payment of up to $250 million to settle more than 10,000...
Pfizer offers up to $250 million to settle Zantac cancer lawsuits, FT reports
AOL· 6 days agoThe drugmaker was set to pay between $200 million and $250 million in the settlement, the newspaper reported, citing two people briefed on the deal. The settlement was disclosed in a court filing ...
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot
KFGO· 4 days ago(Reuters) -Moderna has won a case at the European Patent Office in its dispute with Pfizer and...
2 Top Growth Stocks Down 24% and 50% to Buy With $100
Motley Fool via Yahoo Finance· 5 days agoIf you have even $100 to invest in stocks right now, here are two top healthcare companies that the...
Moderna scores European victory over Pfizer and BioNTech in mRNA patent battle
Endpoints News· 4 days agoThe European Patent Office on Thursday handed a win to Moderna in a long-running patent battle with ...
Pfizer offers up to $250 mln to settle thousands of Zantac cancer lawsuits, FT reports
Reuters· 6 days agoPfizer has agreed offer payment of up to $250 million to settle more than 10,000 lawsuits in the...
Vepdegestrant shows promise in breast cancer trial By Investing.com
Investing.com· 6 days agoArvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: NYSE:PFE) today announced continued positive...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in...
Morningstar· 6 days ago– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in ...